These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26146959)

  • 1. KRAS(G12D)-mediated oncogenic transformation of thyroid follicular cells requires long-term TSH stimulation and is regulated by SPRY1.
    Zou M; Baitei EY; Al-Rijjal RA; Parhar RS; Al-Mohanna FA; Kimura S; Pritchard C; BinEssa H; Alanazi AA; Alzahrani AS; Akhtar M; Assiri AM; Meyer BF; Shi Y
    Lab Invest; 2015 Nov; 95(11):1269-77. PubMed ID: 26146959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.
    Zou M; Baitei EY; Al-Rijjal RA; Parhar RS; Al-Mohanna FA; Kimura S; Pritchard C; Binessa HA; Alzahrani AS; Al-Khalaf HH; Hawwari A; Akhtar M; Assiri AM; Meyer BF; Shi Y
    Oncogene; 2016 Apr; 35(15):1909-18. PubMed ID: 26477313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.
    Franco AT; Malaguarnera R; Refetoff S; Liao XH; Lundsmith E; Kimura S; Pritchard C; Marais R; Davies TF; Weinstein LS; Chen M; Rosen N; Ghossein R; Knauf JA; Fagin JA
    Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1615-20. PubMed ID: 21220306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sprouty1 induces a senescence-associated secretory phenotype by regulating NFκB activity: implications for tumorigenesis.
    Macià A; Vaquero M; Gou-Fàbregas M; Castelblanco E; Valdivielso JM; Anerillas C; Mauricio D; Matias-Guiu X; Ribera J; Encinas M
    Cell Death Differ; 2014 Feb; 21(2):333-43. PubMed ID: 24270409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of TSH in the spontaneous development of asymmetrical thyroid carcinoma in mice with a targeted mutation in a single allele of the thyroid hormone-β receptor.
    Zhao L; Zhu X; Won Park J; Fozzatti L; Willingham M; Cheng SY
    Endocrinology; 2012 Oct; 153(10):5090-100. PubMed ID: 22919057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
    Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
    Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma.
    Lu C; Zhao L; Ying H; Willingham MC; Cheng SY
    Endocrinology; 2010 Apr; 151(4):1929-39. PubMed ID: 20133453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postnatal expression of BRAFV600E does not induce thyroid cancer in mouse models of thyroid papillary carcinoma.
    Shimamura M; Nakahara M; Orim F; Kurashige T; Mitsutake N; Nakashima M; Kondo S; Yamada M; Taguchi R; Kimura S; Nagayama Y
    Endocrinology; 2013 Nov; 154(11):4423-30. PubMed ID: 23970782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.
    Zhu X; Zhao L; Park JW; Willingham MC; Cheng SY
    Neoplasia; 2014 Sep; 16(9):757-69. PubMed ID: 25246276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyrotropin signaling confers more aggressive features with higher genomic instability on BRAF(V600E)-induced thyroid tumors in a mouse model.
    Orim F; Bychkov A; Shimamura M; Nakashima M; Ito M; Matsuse M; Kurashige T; Suzuki K; Saenko V; Nagayama Y; Yamashita S; Mitsutake N
    Thyroid; 2014 Mar; 24(3):502-10. PubMed ID: 23924149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates.
    Al-Salam S; Sharma C; Afandi B; Al Dahmani K; Al-Zahrani AS; Al Shamsi A; Al Kaabi J
    PLoS One; 2020; 15(4):e0231341. PubMed ID: 32315324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation.
    Milewska M; Romano D; Herrero A; Guerriero ML; Birtwistle M; Quehenberger F; Hatzl S; Kholodenko BN; Segatto O; Kolch W; Zebisch A
    PLoS One; 2015; 10(6):e0129859. PubMed ID: 26065894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transgenic mice carrying the human KRAS oncogene under the control of a thyroglobulin promoter: KRAS expression in thyroids analyzed by in situ hybridization.
    Chiappetta G; Fabien N; Picone A; Califano D; Monaco C; de Franciscis V; Vecchio G; Santelli G
    Oncol Res; 1996; 8(2):85-93. PubMed ID: 8859779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mig-6 deficiency cooperates with oncogenic Kras to promote mouse lung tumorigenesis.
    Liu J; Cho SN; Wu SP; Jin N; Moghaddam SJ; Gilbert JL; Wistuba I; DeMayo FJ
    Lung Cancer; 2017 Oct; 112():47-56. PubMed ID: 29191600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.
    Trejo CL; Juan J; Vicent S; Sweet-Cordero A; McMahon M
    Cancer Res; 2012 Jun; 72(12):3048-59. PubMed ID: 22511580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
    Zou M; Baitei EY; Alzahrani AS; BinHumaid FS; Alkhafaji D; Al-Rijjal RA; Meyer BF; Shi Y
    Thyroid; 2014 Aug; 24(8):1256-66. PubMed ID: 24798740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sprouty1 is a candidate tumor-suppressor gene in medullary thyroid carcinoma.
    Macià A; Gallel P; Vaquero M; Gou-Fabregas M; Santacana M; Maliszewska A; Robledo M; Gardiner JR; Basson MA; Matias-Guiu X; Encinas M
    Oncogene; 2012 Aug; 31(35):3961-72. PubMed ID: 22158037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-regulation between oncogenic BRAF(V600E) kinase and the MST1 pathway in papillary thyroid carcinoma.
    Lee SJ; Lee MH; Kim DW; Lee S; Huang S; Ryu MJ; Kim YK; Kim SJ; Kim SJ; Hwang JH; Oh S; Cho H; Kim JM; Lim DS; Jo YS; Shong M
    PLoS One; 2011 Jan; 6(1):e16180. PubMed ID: 21249150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.